Tardive dyskinesia (TD) is rare neurological disorder due to long term use of antipsychotic medications which act on dopamine receptors. It is anticipated that the TD treatment drugs market will show significant market growth over the forecast period owing to some factors such as increasing prevalence of TD, higher number of unmet needs for treatment of TD and expected launch of pipeline drug. Although there are various drugs used in treatment of TD, presently only Valbenazine and Deutetrabenazine are approved by the FDA. Other drugs such as benzodiazepines, botulinum toxin, amantadine, dopamine-depleting agents and calcium channel blockers etc. are also used in symptomatic relief from TD.
The report titled “Tardive dyskinesia (TD) Treatment Drugs Market – Growth, Future Prospects and Competitive Analysis, 2023 – 2030” includes in-depth analysis of TD treatment drugs market for period from 2020 to 2030. For the detailed market study, TD treatment drugs market is categorized on the basis of drug types: Valbenazine, Deutetrabenazine and other drugs (benzodiazepines, botulinum toxin, vitamin E, amantadine, levodopa, reserpine, dopamine-depleting agents and calcium channel blockers etc.)
With a view to present in-depth geographical study, the global TD treatment drugs market is segmented on the basis of key regional markets such as North America, Europe, Latin America, Asia Pacific and Middle East and Africa. For country level analysis, TD treatment drugs market is segmented into Canada, United States, United Kingdom, Germany, rest of Europe, Mexico, Brazil, Rest of Latin America, China, Japan, rest of Asia Pacific, GCC and rest of Middle East and Africa.
This report covers detailed study of qualitative information along with statistical data for better understanding of the current market situation and future market scenario. For better understanding about the ongoing market trends and future market prospects, in-depth information about the market drivers, opportunities and challenges of global TD treatment drugs market are covered in report. Attractive investment propositions and company profiling section provide detail information about the key players involved in global TD treatment drugs market.
Tardive dyskinesia is a neurological movement disorder occurring due to long term use of neuroleptics or anti-psychotic medications. It is considered as a rare disorder as it affects less than 200,000 people in the United States alone. Treatment of TD is highly individualized and the first step is to minimize the use of neuroleptic drugs. Different forms of drugs are used in reducing the symptoms of TD, but only two drugs Valbenazine (Neurocrine Biosciences, Inc.) and deudeutetrabenazine (Teva Pharmaceutical Industries Ltd.) are approved by the US-FDA exclusively for the treatment of TD. It is estimated that Valbenazine and Deutetrabenazine will show significant market growth over the forecast period due to their clinically proven efficacy and target specificity. Other drugs such as benzodiazepines, botulinum toxin, vitamin E, amantadine, levodopa, reserpine, dopamine-depleting agents and calcium channel blockers etc. are also used to reduce symptoms of TD. Prominent pipeline drugs such as SNC-102 (Synchroneuron) expected to assist market growth during the forecast period 2023- 2030.
Tardive dyskinesia is an antipsychotic drug induced movement disorder characterized by evident abnormal involuntary movements. Among the considered geographical markets, North America is the major revenue contributing region in global TD treatment drugs market. Key factors facilitating the dominance of North America are early diagnosis, wide accessibility to treatment drugs, greater number of affected population and well developed healthcare infrastructure. Studies have indicated that more than 50,000 patients are affected with TD in the United States. Ideal pipeline drug (SNC-102) and recent approvals to Valbenazine and Deutetrabenazine are expected to drive significant market growth in North America. TD treatment drugs market in Asia Pacific is set to capture significant position on account of rising treatment awareness among the general population, growing number of affected population and developing healthcare infrastructure.
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Tardive Dyskinesia (TD) Treatment Drugs market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2022-2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Year | 2022 |
| Unit | USD Million |
| Segmentation | |
Drug
| |
|
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report
